Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CLSD | US
0.01
0.90%
Healthcare
Biotechnology
30/06/2024
16/10/2024
1.12
1.13
1.14
1.05
Clearside Biomedical Inc. a biopharmaceutical company focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX an axitinib injectable suspension for suprachoroidal injection which is in Phase 1/2a clinical trial; and CLS-301 an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical Inc. has a collaboration with Bausch Health Arctic Vision REGENXBIO Inc. and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta Georgia.
View LessLow Debt to Equity (< 0.25)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
105.1%1 month
91.1%3 months
74.6%6 months
73.1%-
-
3.93
-1.68
1.40
-2.84
8.53
-
-25.66M
83.72M
83.72M
-
-8.43K
-
-91.20
-1.31K
0.65
0.37
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.60
Range1M
0.60
Range3M
0.73
Rel. volume
0.54
Price X volume
860.99K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Leap Therapeutics Inc | LPTX | Biotechnology | 2.4 | 91.83M | 4.80% | n/a | 0.73% |
MediciNova Inc | MNOV | Biotechnology | 1.85 | 90.74M | 2.21% | n/a | 0.86% |
HilleVax Inc | HLVX | Biotechnology | 1.82 | 90.61M | 1.11% | n/a | 24.92% |
Werewolf Therapeutics Inc. Common Stock | HOWL | Biotechnology | 2.06 | 90.03M | 2.49% | n/a | 35.26% |
Tiziana Life Sciences PLC | TLSA | Biotechnology | 0.88 | 89.33M | -4.35% | n/a | 0.00% |
InflaRx N.V | IFRX | Biotechnology | 1.51 | 88.91M | 2.03% | n/a | 0.00% |
Ovid Therapeutics Inc | OVID | Biotechnology | 1.18 | 83.75M | 2.61% | n/a | 18.40% |
PMV Pharmaceuticals Inc | PMVP | Biotechnology | 1.6 | 83.54M | 7.38% | n/a | 6.06% |
CASI Pharmaceuticals Inc | CASI | Biotechnology | 5.4 | 83.49M | -3.23% | n/a | 167.26% |
Ikena Oncology Inc. Common Stock | IKNA | Biotechnology | 1.72 | 83.00M | 0.58% | n/a | 6.36% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Saga Communications Inc | SGA | Broadcasting - Radio | 14.34 | 89.79M | -0.14% | 14.47 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.5 | 19.04M | 4.17% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.02 | 18.42M | 2.01% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.6542 | 9.49M | -5.19% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2051 | 3.68M | -6.82% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.09 | 2.84M | -0.91% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -0.99% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.42 | 0 | 2.63% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.21 | 0 | 3.19% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.5 | 0 | 1.42% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.84 | 0.53 | Cheaper |
Ent. to Revenue | 8.53 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 3.93 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 74.60 | 72.92 | Par |
Debt to Equity | -1.68 | -1.24 | Cheaper |
Debt to Assets | 1.40 | 0.25 | Expensive |
Market Cap | 83.72M | 3.78B | Emerging |